Aktis Oncology (NASDAQ:AKTS – Get Free Report)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a note issued to investors on Friday, Benzinga reports. They presently have a $35.00 price target on the technology company’s stock. Wedbush’s target price would indicate a potential upside of 92.27% from the company’s previous close.
Several other equities research analysts have also weighed in on AKTS. Oppenheimer initiated coverage on shares of Aktis Oncology in a report on Wednesday, September 9th. They issued an “outperform” rating and a $40.00 target price on the stock. Wall Street Zen lowered shares of Aktis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. BMO Capital Markets initiated coverage on shares of Aktis Oncology in a report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 target price on the stock. JPMorgan Chase & Co. increased their target price on shares of Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Aktis Oncology in a report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Aktis Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $35.63.
View Our Latest Research Report on AKTS
Aktis Oncology Stock Down 1.7%
Aktis Oncology (NASDAQ:AKTS – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The technology company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The company had revenue of $3.38 million for the quarter, compared to analyst estimates of $2.70 million. On average, analysts predict that Aktis Oncology will post -1.85 earnings per share for the current year.
Insider Activity at Aktis Oncology
In related news, Director Ken Herrmann sold 4,856 shares of the firm’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $24.56, for a total transaction of $119,263.36. Following the sale, the director directly owned 3,506 shares in the company, valued at $86,107.36. This trade represents a 58.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 3.30% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in AKTS. Tidal Investments LLC bought a new position in Aktis Oncology in the second quarter valued at $1,839,000. Squarepoint Ops LLC bought a new position in Aktis Oncology in the second quarter valued at $1,237,000. Readystate Asset Management LP bought a new position in Aktis Oncology in the second quarter valued at $967,000. AXQ Capital LP bought a new position in Aktis Oncology in the second quarter valued at $226,000. Finally, Susquehanna International Group LLP bought a new position in Aktis Oncology in the second quarter valued at $278,000. Institutional investors own 28.84% of the company’s stock.
Aktis Oncology Company Profile
Aktis Oncology, Inc is a clinical-stage biopharmaceutical company developing targeted alpha therapies for the treatment of cancer. Its research is focused on creating therapies designed to selectively deliver alpha-particle radiation to tumor cells while limiting exposure to surrounding healthy tissue.
The company’s platform uses proprietary tumor-targeting molecules, including engineered miniproteins, to bind specific targets found on cancer cells and transport radioactive payloads to tumors.
Featured Stories
- Five stocks we like better than Aktis Oncology
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
- Target’s Holiday Blitz: Slashing Prices to Capture Market Share
- NIO Inc.’s Geely Deal Is Really a Bet on Battery-Swap Network Utilization
- Remitly’s September Pullback Tests a Still-Strong Growth Story
Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
